Aprepitant for Chemotherapy-Induced Emesis | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for aprepitant for chemotherapy-induced emesis, with an effective date of May 15, 2026. Here's what billing teams need to know before that date.

CMS aprepitant coverage policy changes affect oncology practices, infusion centers, and hospital outpatient departments billing antiemetic drugs for chemotherapy patients. The policy document does not list specific CPT or HCPCS codes — we'll cover what that means for your billing team below. If you manage aprepitant billing for Medicare patients, this modification requires your attention before May 15, 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Aprepitant for Chemotherapy-Induced Emesis
Policy Code	N/A
Change Type	Modified
Effective Date	May 15, 2026
Impact Level	High
Specialties Affected	Oncology, Hematology/Oncology, Infusion Centers, Hospital Outpatient Departments
Key Action	Review your aprepitant billing guidelines and confirm medical necessity documentation is current before May 15, 2026

---

CMS Aprepitant Coverage Criteria and Medical Necessity Requirements 2026

Aprepitant is a neurokinin-1 (NK1) receptor antagonist. It prevents acute and delayed chemotherapy-induced nausea and vomiting (CINV). Medicare covers it as part of antiemetic therapy for patients undergoing highly or moderately emetogenic chemotherapy regimens.

The real issue here is medical necessity documentation. CMS ties aprepitant reimbursement to specific clinical criteria — the emetogenic potential of the chemotherapy regimen is central to that determination. If your documentation doesn't clearly link the aprepitant to a highly or moderately emetogenic regimen, your claim is exposed.

This coverage policy modification signals CMS is tightening or clarifying how it evaluates aprepitant claims. That pattern is consistent with CMS's broader push over the past two years to reduce inappropriate antiemetic billing in outpatient oncology settings.

What Medicare Has Historically Required for Aprepitant Coverage

Before this modification, CMS required the following to establish medical necessity for aprepitant:

#	Covered Indication Copy
1	The patient is receiving chemotherapy classified as highly or moderately emetogenic
2	The aprepitant regimen is used as part of a combination antiemetic protocol (typically with a 5-HT3 antagonist and dexamethasone)
3	The drug is administered on the appropriate days relative to chemotherapy (Day 1 pre-chemotherapy, with oral follow-up on Days 2 and 3 for standard regimens)

The May 15, 2026 modification may refine these criteria, add documentation requirements, or change how CMS addresses the oral versus injectable formulations. Because the source policy document does not include detailed criteria text, confirm the specific updated requirements directly at the CMS source or with your Medicare Administrative Contractor before the effective date.

Prior Authorization and Aprepitant Under Medicare

Traditional Medicare (Parts A and B) does not require prior authorization for most Part B drugs. However, aprepitant prescribed under Medicare Part D — the outpatient prescription drug benefit — does go through your patient's Part D plan's prior authorization process.

This distinction matters for your billing team. Know which setting you're billing from. Hospital outpatient and infusion center claims go through Part B. Oral aprepitant dispensed at a pharmacy goes through Part D. The coverage policy and prior auth requirements differ between those two pathways.

---

CMS Aprepitant Exclusions and Non-Covered Indications

CMS does not cover aprepitant for nausea and vomiting unrelated to chemotherapy. Using it for postoperative nausea, radiation-induced nausea, or general nausea without a documented emetogenic chemotherapy regimen will result in claim denial.

Aprepitant is also not covered when the chemotherapy regimen is classified as low or minimal emetogenic risk. If your documentation doesn't support the emetogenic classification, CMS treats that as a medical necessity failure — not a coding error.

The distinction between fosaprepitant (the IV prodrug) and oral aprepitant matters for coverage purposes too. Each formulation has different billing pathways and coverage logic under Medicare. Billing one when you administered the other is a coding accuracy issue that can trigger audits.

---

Coverage Indications at a Glance

---

CMS Aprepitant Billing Guidelines and Action Items 2026

The modification effective May 15, 2026 requires action now — not after the date hits. Here's what to do.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Aprepitant Under CMS Policy

The CMS policy document for this modification does not list specific CPT, HCPCS, or ICD-10 codes. We do not invent codes here. What follows is context to help your billing team identify the correct codes — but verify each code against the current CMS fee schedule and your MAC's guidance before billing.

Commonly Used Codes in Aprepitant Billing (Verify Before Use)

Your billing team likely already uses codes for aprepitant administration. The policy does not specify them, so confirm the following apply to your claims with your billing consultant or MAC:

• HCPCS codes for fosaprepitant (IV formulation) and aprepitant (oral formulation) — both exist in the HCPCS drug table and are updated annually
• Administration codes for IV drug infusion when fosaprepitant is given in the infusion center setting
• ICD-10-CM codes for chemotherapy-induced nausea and vomiting and for the underlying malignancy driving the chemotherapy

Because the policy does not enumerate codes, your safest path is to cross-reference your existing charge capture against the CMS HCPCS drug file and your MAC's drug payment table for 2026.

A Note on Code Verification

When a CMS policy modification doesn't list codes directly, that's not a reason to assume your current codes are fine. It's a reason to verify them. Pull the current HCPCS code for fosaprepitant, confirm the descriptor matches what you're administering, and check the reimbursement rate under the 2026 Medicare Part B drug pricing file.

If you're unsure whether your current codes align with the updated policy, talk to your billing consultant before the May 15, 2026 effective date. A code mismatch found post-audit costs far more than a preemptive review.

---